CoChat
Sign Up
Cited by 20Renin-Angiotensin System StudiesPregnancy and preeclampsia studiesCoagulation, Bradykinin, Polyphosphates, and Angioedema

Physiological and pathological roles of Ang II and Ang- (1-7) in the female reproductive system

Open access
Liu, Yuanyuan, Hao, Haomeng, Lan, Tingting, Jia, Rui, Cao, Mingya, Zhou, Liang, Zhao, Zhiming, Pan, Wensen·2022·Frontiers in Endocrinology
DOI 10.3389/fendo.2022.1080285PMC PMC9817105
Open this paper in CoChat — free accountOpen PDF

Abstract

The local Renin-Angiotensin System (RAS) has been demonstrated to exist in a wide range of tissues and organs, In the female reproductive system, it is mainly found in the ovary, uterus and placenta. The RAS system is made up of a series of active substances and enzymes, in addition to the circulating endocrine renin-angiotensin system. The active peptides Angiotensin II (Ang II) and Angiotensin (1-7) (Ang-(1-7)), in particular, appear to have distinct activities in the local RAS system, which also controls blood pressure and electrolytes. Therefore, in addition to these features, angiotensin and its receptors in the reproductive system seemingly get involved in reproductive processes, such as follicle growth and development, as well as physiological functions of the placenta and uterus. In addition, changes in local RAS components may induce reproductive diseases as well as pathological states such as cancer. In most tissues, Ang II and Ang- (1-7) seem to maintain antagonistic effects, but this conclusion is not always true in the reproductive system, where they play similar functions in some physiological and pathological roles. This review investigated how Ang II, Ang- (1-7) and their receptors were expressed, localized, and active in the female reproductive system. This review also summarized their effects on follicle development, uterine and placental physiological functions. The changes of local RAS components in a series of reproductive system diseases including infertility related diseases and cancer and their influence on the occurrence and development of diseases were elucidated. This article reviews the physiological and pathological roles of Ang II and Ang- (1-7) in female reproductive system,a very intricate system of tissue factors that operate as agonists and antagonists was found. Besides, the development of novel therapeutic strategies targeting components of this system may be a research direction in future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1080285

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the human ovary, local RAS is involved in supporting oogenesis, regulating ovulation function, synthesizing steroid hormones, and mediating gonadotropin function.

    “In the human ovary, local RAS is involved in many important physiological processes such as supporting oogenesis, regulating ovulation function, synthesizing steroid hormones, and mediating gonadotropin function [7, 23–25].”

    From Transplantation of human umbilical cord-derived mesenchymal stem cells improves age-related ovarian functional decline via regulating the local renin–angiotensin system on inflammation and oxidative stress (2024) · cites this paper as [23]

    The ovarian physiology section reports roles for Ang II and Ang-(1-7) in oocyte maturation and ovulation, and links Ang-(1-7) in human follicular fluid with developed oocytes. The Conclusion says RAS affects hormone production, but does not establish steroid-hormone synthesis specifically in the human ovary. The ovarian section reports elevated Ang-(1-7) in gonadotropin-stimulated women, not that local RAS mediates gonadotropin function; it also cautions that ovarian effects vary by species. Page numbers are unavailable in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 135

  1. [1]Herr D Bekes I Wulff C. Local renin-angiotensin system in the reproductive system. Front Endocrinol (2013) 4(150): 00150. doi: 10.3389/fendo.2013.00150 PMC3798827 24151488 · DOI · Paper page
  2. [3]Mahon JM Carr RD Nicol AK Henderson IW. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens (1994) 12(12): 1377–81. doi: 10.1097/00004872-199412000-00010 7706697 · DOI
  3. [4]Henarejos-Castillo I Sebastian-Leon P Devesa-Peiro A Pellicer A Diaz-Gimeno P. SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle. Fertil Steril (2020) 114(2): 223–32. doi: 10.1016/j.fertnstert.2020.06.026 PMC7298504 32641214 · DOI
  4. [5]Shabanian S Khazaie M Ferns GA Arjmand MH. Local renin-angiotensin system molecular mechanisms in intrauterine adhesions formation following gynecological operations, new strategy for novel treatment. J Obstet Gynaecol (2022) 42(6): 1613–8. doi: 10.1080/01443615.2022.2036972 35260037 · DOI
  5. [7]Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev (1977) 57(2): 313–70. doi: 10.1152/physrev.1977.57.2.313 191856 · DOI
  6. [8]Hersh EV Wolff M Moore PA Theken KN Daniell H. A pair of "ACEs". J Dent Res (2022) 101(1): 5– 10. doi: 10.1177/00220345211047510 34689655 PMC8721725 · DOI
  7. [9]Rice GI Thomas DA Grant PJ Turner AJ Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J (2004) 383(Pt 1): 45– 51. doi: 10.1042/BJ20040634 15283675 PMC1134042 · DOI
  8. [10]Santos RAS Sampaio WO Alzamora AC Motta-Santos D Alenina N Bader M. The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: Focus on angiotensin-(1-7). Physiol Rev (2018) 98(1): 505–53. doi: 10.1152/physrev.00023.2016 PMC7203574 29351514 · DOI · Paper page
  9. [11]Vickers C Hales P Kaushik V Dick L Gavin J Tang J. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem (2002) 277(17): 14838–43. doi: 10.1074/jbc.M200581200 11815627 · DOI
  10. [12]Brosnihan KB Neves LA Anton L Joyner J Valdes G Merrill DC. Enhanced expression of ang-(1-7) during pregnancy. Braz J Med Biol Res (2004) 37(8): 1255–62. doi: 10.1590/S0100-879X2004000800017 15273828 · DOI
  11. [13]Teixeira LB Parreiras-E-Silva LT Bruder-Nascimento T Duarte DA Simões SC Costa RM. Ang-(1-7) is an endogenous β-arrestin-biased agonist of the AT(1) receptor with protective action in cardiac hypertrophy. Sci Rep (2017) 7(1): 017– 12074. doi: 10.1038/s41598-017-12074-3 PMC5605686 28928410 · DOI
  12. [14]Bosnyak S Jones ES Christopoulos A Aguilar MI Thomas WG Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (2011) 121(7): 297– 303. doi: 10.1042/CS20110036 21542804 · DOI
  13. [15]Gironacci MM Adamo HP Corradi G Santos RA Ortiz P Carretero OA. Angiotensin (1-7) induces MAS receptor internalization. Hypertension (2011) 58(2): 176–81. doi: 10.1161/HYPERTENSIONAHA.111.173344 PMC3141282 21670420 · DOI
  14. [16]Ferrario CM Groban L Wang H Sun X VonCannon JL Wright KN. The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts. Kidney Int Suppl (2011) 12(1): 36– 47. doi: 10.1016/j.kisu.2021.11.002 PMC9073260 35529089 · DOI
  15. [17]Pountain SJ Pipkin FB Hunter MG. The ontogeny of components of the renin-angiotensin system in the porcine fetal ovary. Anim Reprod Sci (2010) 117(1-2): 119–26. doi: 10.1016/j.anireprosci.2009.03.006 19372013 · DOI
  16. [18]Cavallo IK Dela Cruz C Oliveira ML Del Puerto HL Dias JA Lobach VN. Angiotensin-(1-7) in human follicular fluid correlates with oocyte maturation. Hum Reprod (2017) 32(6): 1318–24. doi: 10.1093/humrep/dex072 28402544 · DOI · Paper page
  17. [19]Yoshimura T Ito M Matsui K Okamura H. Effects of highly purified eicosapentaenoic acid on vascular reactivity to angiotensin II and norepinephrine in pregnant rabbits. Artery (1997) 22(5): 242–50. 9209697
  18. [20]Ferreira R Gasperin B Santos J Rovani M Santos RA Gutierrez K. Angiotensin II profile and mRNA encoding RAS proteins during bovine follicular wave. J Renin Angiotensin Aldosterone Syst (2011) 12(4): 475–82. doi: 10.1177/1470320311403786 21459786 · DOI
  19. [21]Giometti IC Bertagnolli AC Ornes RC da Costa LF Carambula SF Reis AM. Angiotensin II reverses the inhibitory action produced by theca cells on bovine oocyte nuclear maturation. Theriogenology (2005) 63(4): 1014–25. doi: 10.1016/j.theriogenology.2004.05.022 15710189 · DOI
  20. [22]Erman A Chen-Gal B van Dijk DJ Sulkes J Kaplan B Boner G. Ovarian angiotensin-converting enzyme activity in humans: relationship to estradiol, age, and uterine pathology. J Clin Endocrinol Metab (1996) 81(3): 1104–7. doi: 10.1210/jcem.81.3.8772583 8772583 · DOI
  21. [23]Li YH Jiao LH Liu RH Chen XL Wang H Wang WH.. Localization of angiotensin II in pig ovary and its effects on oocyte maturation in vitro. Theriogenology (2004) 61(2-3): 447–59. doi: 10.1016/S0093-691X(03)00246-2 14662143 · DOI
  22. [24]Obermüller N Gentili M Gauer S Gretz N Weigel M Geiger H. Immunohistochemical and mRNA localization of the angiotensin II receptor subtype 2 (AT2) in follicular granulosa cells of the rat ovary. J Histochem Cytochem (2004) 52(4): 545–8. doi: 10.1177/002215540405200413 15034006 · DOI
  23. [25]Tanaka M Ohnishi J Ozawa Y Sugimoto M Usuki S Naruse M. Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Commun (1995) 207(2): 593–8. doi: 10.1006/bbrc.1995.1229 7864848 · DOI
  24. [26]Kotani E Sugimoto M Kamata H Fujii N Saitoh M Usuki S. Biological roles of angiotensin II via its type 2 receptor during rat follicle atresia. Am J Physiol (1999) 276(1): E25–33. doi: 10.1152/ajpendo.1999.276.1.E25 9886947 · DOI
  25. [27]Peña O Palumbo A González-Fernández R Hernández J Naftolin F Avila J. Expression of angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors in human granulosa-lutein (GL) cells: correlation with infertility diagnoses. Fertil Steril (2010) 93(5): 1601–8. doi: 10.1016/j.fertnstert.2009.03.092 19524223 · DOI · Paper page
  26. [28]Kalenga MK de Gasparo M de Hertogh R Whitebread S Vankrieken L Thomas K. [Angiotensin II receptors in the human placenta are type AT1]. Reprod Nutr Dev (1991) 31(3): 257–67. 1878151
  27. [29]Lumbers ER Wang Y Delforce SJ Corbisier de Meaultsart C Logan PC Mitchell MD. Decidualisation of human endometrial stromal cells is associated with increased expression and secretion of prorenin. Reprod Biol Endocrinol (2015) 13(129): 015– 0127. doi: 10.1186/s12958-015-0127-8 PMC4658797 26608077 · DOI
  28. [30]Ahmed A Li XF Shams M Gregory J Rollason T Barnes NM. Localization of the angiotensin II and its receptor subtype expression in human endometrium and identification of a novel high-affinity angiotensin II binding site. J Clin Invest (1995) 96(2): 848–57. doi: 10.1172/JCI118131 PMC185271 7635979 · DOI
  29. [31]Pringle KG Delforce SJ Wang Y Ashton KA Proietto A Otton G. Renin-angiotensin system gene polymorphisms and endometrial cancer. Endocr Connect (2016) 5(3): 128–35. doi: 10.1530/EC-15-0112 PMC5002951 27068935 · DOI
  30. [32]Rosenfeld CR DeSpain K Word RA Liu XT. Differential sensitivity to angiotensin II and norepinephrine in human uterine arteries. J Clin Endocrinol Metab (2012) 97(1): 138–47. doi: 10.1210/jc.2011-1818 PMC3251932 22031522 · DOI
  31. [33]Gan L Liu D Liu J Chen E Chen C Liu L. CD38 deficiency alleviates ang II-induced vascular remodeling by inhibiting small extracellular vesicle-mediated vascular smooth muscle cell senescence in mice. Signal Transduct Target Ther (2021) 6(1): 021– 00625. doi: 10.1038/s41392-021-00625-0 PMC8192533 34112762 · DOI
  32. [34]Henriet P Gaide Chevronnay HP Marbaix E. The endocrine and paracrine control of menstruation. Mol Cell Endocrinol (2012) 358(2): 197– 207. doi: 10.1016/j.mce.2011.07.042 21820486 · DOI
  33. [35]Neves LA Stovall K Joyner J Valdés G Gallagher PE Ferrario CM. ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol (2008) 294(1): 31. 17977916
  34. [36]Vaz-Silva J Tavares RL Ferreira MC Honorato-Sampaio K Cavallo IK Santos RA. Tissue specific localization of angiotensin-(1-7) and its receptor mas in the uterus of ovariectomized rats. J Mol Histol (2012) 43(5): 597– 602. doi: 10.1007/s10735-012-9427-x 22684246 · DOI
  35. [37]Shan T Zhang L Zhao C Chen W Zhang YA. Angiotensin-(1-7) and angiotensin II induce the transdifferentiation of human endometrial epithelial cells in vitro. Mol Med Rep (2014) 9(6): 2180–6. doi: 10.3892/mmr.2014.2128 PMC4055473 24718590 · DOI
  36. [38]Shan T Shang W Zhang L Zhao C Chen W Zhang Y. Effect of angiotensin-(1-7) and angiotensin II on the proliferation and activation of human endometrial stromal cells in vitro. Int J Clin Exp Pathol (2015) 8(8): 8948–57. PMC4583868 26464636
  37. [39]Zimmerman D Burns KD. Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin Sci (2012) 123(6): 333–46. doi: 10.1042/CS20120111 22639821 · DOI
  38. [40]Lauer D Slavic S Sommerfeld M Thöne-Reineke C Sharkovska Y Hallberg A. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart. Hypertension (2014) 63(3): 30. doi: 10.1161/HYPERTENSIONAHA.113.02522 24379181 · DOI
  39. [41]Maltepe E Fisher SJ. Placenta: the forgotten organ. Annu Rev Cell Dev Biol (2015) 31: 523–52. doi: 10.1146/annurev-cellbio-100814-125620 26443191 · DOI · Paper page
  40. [42]Thapa L He CM Chen HP. Study on the expression of angiotensin II (ANG II) receptor subtype 1 (AT1R) in the placenta of pregnancy-induced hypertension. Placenta (2004) 25(7): 637–41. doi: 10.1016/j.placenta.2004.01.026 15193870 · DOI
  41. [43]Lumbers ER Pringle KG. Roles of the circulating renin-angiotensin-aldosterone system in human pregnancy. Am J Physiol Regul Integr Comp Physiol (2014) 306(2): 2. doi: 10.1152/ajpregu.00034.2013 24089380 · DOI
  42. [44]Hagemann A Nielsen AH Poulsen K. The uteroplacental renin-angiotensin system: a review. Exp Clin Endocrinol (1994) 102(3): 252–61. doi: 10.1055/s-0029-1211289 7995347 · DOI
  43. [45]Leal CRV Costa LB Ferreira GC Ferreira AM Reis FM Simões E. Renin-angiotensin system in normal pregnancy and in preeclampsia: A comprehensive review. Pregnancy Hypertens (2022) 28: 15– 20. doi: 10.1016/j.preghy.2022.01.011 35149272 · DOI
  44. [46]Pan P Fu H Zhang L Huang H Luo F Wu W. Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol (2010) 11(36): 1471– 2121. doi: 10.1186/1471-2121-11-36 PMC2885991 20500895 · DOI
  45. [47]Delforce SJ Lumbers ER Morosin SK Wang Y Pringle KG. The angiotensin II type 1 receptor mediates the effects of low oxygen on early placental angiogenesis. Placenta (2019) 75: 54– 61. doi: 10.1016/j.placenta.2018.12.001 30712667 · DOI
  46. [48]Anton L Merrill DC Neves LA Gruver C Moorefield C Brosnihan KB. Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in vitro study. Reprod Biol Endocrinol (2010) 8(135): 1477– 7827. doi: 10.1186/1477-7827-8-135 PMC2989977 21050477 · DOI
  47. [49]Espino YSS Martinez-Portilla RJ Torres-Torres J Solis-Paredes JM Estrada-Gutierrez G Hernandez-Pacheco JA. Novel ratio soluble fms-like tyrosine kinase-1/Angiotensin-II (sFlt-1/ANG-II) in pregnant women is associated with critical illness in COVID-19. Viruses (2021) 13(10): 1906. doi: 10.3390/v13101906 34696336 PMC8538263 · DOI
  48. [50]Oogaki Y Ozawa R Seshima K Shinoda R Torii Y Takahashi H. Uncaria tomentosa extract (AC-11) improves pregnancy hypertension together with suppression of sFlt-1 and sEng. Pregnancy Hypertens (2021) 26: 127–32. doi: 10.1016/j.preghy.2021.10.013 34773881 · DOI
  49. [51]Zhou CC Ahmad S Mi T Xia L Abbasi S Hewett PW. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res (2007) 100(1): 88– 95. doi: 10.1161/01.RES.0000254703.11154.18 17158338 PMC3266823 · DOI
  50. [52]Espinoza J Betancourt A Belfort MA Shamshirsaz AA Fox KA Yallampalli C. Placental growth factor blunts uterine artery responses to angiotensin II. Bjog (2019) 126(8): 1058–64. doi: 10.1111/1471-0528.15656 PMC7004274 30771259 · DOI
  51. [53]Hering L Herse F Geusens N Verlohren S Wenzel K Staff AC. Effects of circulating and local uteroplacental angiotensin II in rat pregnancy. Hypertension (2010) 56(2): 311–8. doi: 10.1161/HYPERTENSIONAHA.110.150961 20530295 · DOI
  52. [54]Tamanna S Lumbers ER Morosin SK Delforce SJ Pringle KG. ACE2: a key modulator of the renin-angiotensin system and pregnancy. Am J Physiol Regul Integr Comp Physiol (2021) 321(6): R833–43. doi: 10.1152/ajpregu.00211.2021 PMC8862784 34668428 · DOI
  53. [55]Tamanna S Morosin SK Delforce SJ van Helden DF Lumbers ER Pringle KG. Renin-angiotensin system (RAS) enzymes and placental trophoblast syncytialisation. Mol Cell Endocrinol (2022) 547(111609): 22. doi: 10.1016/j.mce.2022.111609 35202745 · DOI
  54. [56]Schmid M Sollwedel A Thuere C Wafula PO Zenclussen ML Müller DN. Murine pre-eclampsia induced by unspecific activation of the immune system correlates with alterations in the eNOS and AT1 receptor expression in the kidneys and placenta. Placenta (2007) 28(7): 688– 700. doi: 10.1016/j.placenta.2006.10.008 17129602 · DOI
  55. [57]Cornelius DC Amaral LM Harmon A Wallace K Thomas AJ Campbell N. An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia. Am J Physiol Regul Integr Comp Physiol (2015) 309(8): 19. doi: 10.1152/ajpregu.00154.2015 PMC4666948 26290102 · DOI
  56. [58]Blumenfeld Z. The ovarian hyperstimulation syndrome. Vitam Horm (2018) 107: 423–51. doi: 10.1016/bs.vh.2018.01.018 29544639 · DOI
  57. [59]Manno M Tomei F. Renin-angiotensin system activation during severe OHSS: cause or effect? Fertil Steril (2008) 89(2): 488. doi: 10.1016/j.fertnstert.2007.12.003 18275884 · DOI
  58. [60]Navot D Margalioth EJ Laufer N Birkenfeld A Relou A Rosler A. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril (1987) 48(1): 57– 61. doi: 10.1016/S0015-0282(16)59290-5 2439386 · DOI
  59. [61]Delbaere A Bergmann PJ Gervy-Decoster C Camus M de Maertelaer V Englert Y. Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod (1997) 12(2): 236–40. doi: 10.1093/humrep/12.2.236 9070702 · DOI
  60. [62]Ong AC Eisen V Rennie DP Homburg R Lachelin GC Jacobs HS. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clin Endocrinol (1991) 34(1): 43–9. doi: 10.1111/j.1365-2265.1991.tb01734.x 2004471 · DOI
  61. [63]Delbaere A Bergmann PJ Englert Y. Features of the renin-angiotensin system in ascites and pleural effusion during severe ovarian hyperstimulation syndrome. J Assist Reprod Genet (1997) 14(5): 241–4. doi: 10.1007/BF02765823 PMC3454728 9147235 · DOI
  62. [64]Morris RS. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod (1995) 10(6): 1355–8. doi: 10.1093/HUMREP/10.6.1355 7593495 · DOI
  63. [65]Sahin Y. Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Gynecol Endocrinol (1997) 11(4): 231–6. doi: 10.3109/09513599709152539 9272418 · DOI
  64. [66]Ando H. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod (2003) 18(6): 1219–22. doi: 10.1093/humrep/deg268 12773449 · DOI
  65. [67]Ata B. Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome. Fertil Steril (2008) 90(3): 531–6. doi: 10.1016/j.fertnstert.2007.07.1309 18001715 · DOI
  66. [68]Ndefo UA Eaton A Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T (2013) 38(6): 336–55. PMC3737989 23946629
  67. [69]Jaatinen TA Matinlauri I Anttila L Koskinen P Erkkola R Irjala K. Serum total renin is elevated in women with polycystic ovarian syndrome. Fertil Steril (1995) 63(5): 1000–4. doi: 10.1016/S0015-0282(16)57537-2 7720907 · DOI
  68. [70]Alphan Z Berberoglu Z Gorar S Candan Z Aktas A Aral Y. Increased total renin levels but not angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome. Med Princ Pract (2013) 22(5): 475–9. doi: 10.1159/000351572 PMC5586791 23899907 · DOI
  69. [71]Arefi S Mottaghi S Sharifi AM. Studying the correlation of renin-angiotensin-system (RAS) components and insulin resistance in polycystic ovary syndrome (PCOs). Gynecol Endocrinol (2013) 29(5): 470–3. doi: 10.3109/09513590.2013.769513 23461768 · DOI
  70. [72]Pereira VM Reis FM Casalechi M Reis AM. Angiotensin-(1-7), angiotensin-converting enzyme 2 and mas receptor in rat polycystic ovaries. Protein Pept Lett (2021) 28(3): 249–54. doi: 10.2174/0929866527666200826104410 32851948 · DOI
  71. [73]Qin S Zhou YJ Liu Y Shen HM Li XD Yan X. [Expression and significance of ACE2-Ang-(1-7)-Mas axis in the endometrium of patients with polycystic ovary syndrome]. Zhonghua Yi Xue Za Zhi (2013) 93(25): 1989–92. 24169251
  72. [74]Underwood PC Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep (2013) 15(1): 59– 70. doi: 10.1007/s11906-012-0323-2 23242734 PMC3551270 · DOI
  73. [75]Zhao S Sun W Jiang P. Role of the ACE2/Ang-(1-7)/Mas axis in glucose metabolism. Rev Cardiovasc Med (2021) 22(3): 769–77. doi: 10.31083/j.rcm2203083 34565075 · DOI
  74. [76]Souza-Mello V. Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. World J Hepatol (2017) 9(2): 74–9. doi: 10.4254/wjh.v9.i2.74 PMC5241531 28144388 · DOI
  75. [77]Hacihanefioglu B Somunkiran A Mahmutoglu I Sercelik A Toptani S Kervancioglu E. Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertil Steril (2002) 77(3): 526–8. doi: 10.1016/S0015-0282(01)03210-1 11872207 · DOI
  76. [78]Deepika ML Reddy KR Rani VU Balakrishna N Latha KP Jahan P. Do ACE I/D gene polymorphism serve as a predictive marker for age at onset in PCOS? J Assist Reprod Genet (2013) 30(1): 125–30. doi: 10.1007/s10815-012-9906-8 PMC3553350 23232975 · DOI
  77. [79]Karabulut A Turgut S Turgut G. Angiotensin converting enzyme gene insertion/deletion polymorphism in patients with polycystic ovary syndrome. Gynecol Endocrinol (2010) 26(6): 393–8. doi: 10.3109/09513591003632167 20170341 · DOI
  78. [80]Ożegowska K Bogacz A Bartkowiak-Wieczorek J Seremak-Mrozikiewicz A Pawelczyk L. Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. Mol Med Rep (2016) 14(6): 5401–7. doi: 10.3892/mmr.2016.5910 27840997 · DOI
  79. [81]Ma WD Fan P Liu HW Liu QQ Hu KF Bai H. [Clinical study of the impact of ACE I/D gene variation on the clinical parameters of patients with polycystic ovary syndrome]. Sichuan Da Xue Xue Bao Yi Xue Ban (2021) 52(5): 877–82. doi: 10.12182/20210960207 PMC10408884 34622609 · DOI
  80. [82]Sun J Fan H Che Y Cao Y Wu X Sun HX. Association between ACE gene I/D polymorphisms and hyperandrogenism in women with polycystic ovary syndrome (PCOS) and controls. BMC Med Genet (2009) 10(64): 1471– 2350. doi: 10.1186/1471-2350-10-64 PMC2714507 19602270 · DOI
  81. [83]Beyazit F Ayhan S Celik HT Gungor T. Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet (2015) 292(2): 415–20. doi: 10.1007/s00404-015-3661-x 25693759 · DOI
  82. [84]Suganuma T Ino K Shibata K Kajiyama H Nagasaka T Mizutani S. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res (2005) 11(7): 2686–94. doi: 10.1158/1078-0432.CCR-04-1946 15814650 · DOI
  83. [85]Cotter TP Kealy NP Duggan PF Curtain A Bredin CP. Elevated serum angiotensin converting enzyme levels in metastatic ovarian dysgerminoma. Respir Med (1997) 91(4): 237–9. doi: 10.1016/S0954-6111(97)90045-7 9156148 · DOI
  84. [86]Zhang Q Yu S Lam MMT Poon TCW Sun L Jiao Y. Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress. J Exp Clin Cancer Res (2019) 38(1): 019– 1127. doi: 10.1186/s13046-019-1127-x PMC6407256 30845964 · DOI
  85. [87]Song L Zhang SL Bai KH Yang J Xiong HY Li X. Serum agonistic autoantibodies against type-1 angiotensin II receptor titer in patients with epithelial ovarian cancer: a potential role in tumor cell migration and angiogenesis. J Ovarian Res (2013) 6(1): 1757– 2215. doi: 10.1186/1757-2215-6-22 PMC3626713 23561060 · DOI
  86. [88]Ino K Shibata K Kajiyama H Yamamoto E Nagasaka T Nawa A. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer (2006) 94(4): 552–60. doi: 10.1038/sj.bjc.6602961 PMC2361172 16434990 · DOI
  87. [89]Domińska K Urbanek KA Kowalska K Habrowska-Górczyńska DE Kozieł MJ Ochędalski T. The influence of angiotensin peptides on survival and motility of human high-grade serous ovarian cancer cells in serum starvation conditions. Int J Mol Sci (2021) 23(1): 52. doi: 10.3390/ijms23010052 35008474 PMC8744539 · DOI
  88. [90]Park YA Choi CH Do IG Song SY Lee JK Cho YJ. Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. Gynecol Oncol (2014) 135(1): 108–17. doi: 10.1016/j.ygyno.2014.06.031 25014541 · DOI
  89. [91]Saunders PTK Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic prospects. Cell (2021) 184(11): 2807–24. doi: 10.1016/j.cell.2021.04.041 34048704 · DOI
  90. [92]Nakajima T Chishima F Nakao T Hayashi C Kasuga A Shinya K. The expression of MAS1, an angiotensin (1-7) receptor, in the eutopic proliferative endometria of endometriosis patients. Gynecol Obstet Invest (2018) 83(6): 600–7. doi: 10.1159/000490561 29982252 · DOI
  91. [93]Hsieh YY Chang CC Chen SY Chen CP Lin WH Tsai FJ. XRCC1 399 arg-related genotype and allele, but not XRCC1 His107Arg, XRCC1 Trp194Arg, KCNQ2, AT1R, and hOGG1 polymorphisms, are associated with higher susceptibility of endometriosis. Gynecol Endocrinol (2012) 28(4): 305–9. doi: 10.3109/09513590.2011.631624 22084859 · DOI
  92. [94]Nenicu A Körbel C Gu Y Menger MD Laschke MW. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. Hum Reprod (2014) 29(5): 1011–24. doi: 10.1093/humrep/deu035 24578472 · DOI
  93. [95]Chen ZZ Gong X. Tanshinone IIA contributes to the pathogenesis of endometriosis via renin angiotensin system by regulating the dorsal root ganglion axon sprouting. Life Sci (2020) 240(117085): 20. doi: 10.1016/j.lfs.2019.117085 31759042 · DOI
  94. [96]Kowalczyńska LJ Ferenc T Wojciechowski M Mordalska A Pogoda K Malinowski A. Endometriosis and RAS system gene polymorphisms: the association of ACE A2350G polymorphism with endometriosis in polish individuals. DNA Cell Biol (2014) 33(5): 328–35. doi: 10.1089/dna.2013.2255 24571615 · DOI
  95. [97]Hsieh YY Chang CC Tsai FJ Hsu CM Lin CC Tsai CH. Angiotensin I-converting enzyme ACE 2350*G and ACE-240*T-related genotypes and alleles are associated with higher susceptibility to endometriosis. Mol Hum Reprod (2005) 11(1): 11–4. doi: 10.1093/molehr/gah131 15531592 · DOI
  96. [98]Hsieh YY Lee CC Chang CC Wang YK Yeh LS Lin CS. Angiotensin I-converting enzyme insertion-related genotypes and allele are associated with higher susceptibility of endometriosis and leiomyoma. Mol Reprod Dev (2007) 74(7): 808–14. doi: 10.1002/mrd.20474 17186537 · DOI
  97. [99]Trovó de Marqui AB. Genetic polymorphisms and endometriosis: contribution of genes that regulate vascular function and tissue remodeling. Rev Assoc Med Bras (1992) 58(5): 620–32. doi: 10.1590/s0104-42302012000500022 23090236 · DOI
  98. [100]Kowalczyńska LJ Tomasz F Wojciechowski M Mordalska A Pogoda K Malinowski A. ACE I/D polymorphism in polish patients with endometriosis. Ginekol Pol (2011) 82(2): 102–7. 21568223
  99. [101]Lamp M Saare M Laisk T Karro H Kadastik U Metspalu A. Genetic variations in vascular endothelial growth factor but not in angiotensin I-converting enzyme genes are associated with endometriosis in Estonian women. Eur J Obstet Gynecol Reprod Biol (2010) 153(1): 85–9. doi: 10.1016/j.ejogrb.2010.07.021 20685027 · DOI
  100. [102]Amant F Moerman P Neven P Timmerman D Van Limbergen E Vergote I. Endometrial cancer. Lancet (2005) 366(9484): 491– 505. doi: 10.1016/S0140-6736(05)67063-8 16084259 · DOI
  101. [103]Delforce SJ Lumbers ER Corbisier de Meaultsart C Wang Y Proietto A Otton G. Expression of renin-angiotensin system (RAS) components in endometrial cancer. Endocr Connect (2017) 6(1): 9– 19. doi: 10.1530/EC-16-0082 27956412 PMC5302162 · DOI
  102. [104]Nowakowska M Matysiak-Burzyńska Z Kowalska K Płuciennik E Domińska K Piastowska-Ciesielska AW. Angiotensin II promotes endometrial cancer cell survival. Oncol Rep (2016) 36(2): 1101–10. doi: 10.3892/or.2016.4887 27349856 · DOI
  103. [105]Matysiak-Burzyńska ZE Nowakowska M Domińska K Kowalska K Płuciennik E Piastowska-Ciesielska AW. Silencing of angiotensin receptor 1 interferes with angiotensin II oncogenic activity in endometrial cancer. J Cell Biochem (2018) 119(11): 9110–21. doi: 10.1002/jcb.27174 30105775 · DOI
  104. [106]Watanabe Y Shibata K Kikkawa F Kajiyama H Ino K Hattori A. Adipocyte-derived leucine aminopeptidase suppresses angiogenesis in human endometrial carcinoma via renin-angiotensin system. Clin Cancer Res (2003) 9(17): 6497–503. 14695154
  105. [107]Correa-Noronha SA Noronha SM Alecrim C Mesquita Ade C Brito GS Junqueira MG. Association of angiotensin-converting enzyme I gene I/D polymorphism with endometrial but not with ovarian cancer. Gynecol Endocrinol (2012) 28(11): 889–91. doi: 10.3109/09513590.2012.683060 22571796 · DOI
  106. [108]Freitas-Silva M Pereira D Coelho C Bicho M Lopes C Medeiros R. Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women. Cancer Genet Cytogenet (2004) 155(1): 42–6. doi: 10.1016/j.cancergencyto.2004.03.020 15527901 · DOI
  107. [109]Jung E Romero R Yeo L Gomez-Lopez N Chaemsaithong P Jaovisidha A. The etiology of preeclampsia. Am J Obstet Gynecol (2022) 226(2S): S844–66. doi: 10.1016/j.ajog.2021.11.1356 PMC8988238 35177222 · DOI
  108. [110]Roberts JM Rich-Edwards JW McElrath TF Garmire L Myatt L Global Pregnancy Collaboration. Subtypes of preeclampsia: Recognition and determining clinical usefulness. Hypertension (2021) 77(5): 1430–41. doi: 10.1161/HYPERTENSIONAHA.120.14781 PMC8103569 33775113 · DOI · Paper page
  109. [111]Overton E Tobes D Lee A. Preeclampsia diagnosis and management. Best Pract Res Clin Anaesthesiol (2022) 36(1): 107–21. doi: 10.1016/j.bpa.2022.02.003 35659948 · DOI
  110. [112]Chappell LC Cluver CA Kingdom J Tong S. Pre-eclampsia. Lancet (2021) 398(10297): 341–54. doi: 10.1016/S0140-6736(20)32335-7 34051884 · DOI
  111. [113]van der Graaf AM Toering TJ van der Wiel MWK Frenay AS Wallukat G Dechend R. Angiotensin II responsiveness after preeclampsia: translational data from an experimental rat model and early-onset human preeclampsia. J Hypertens (2017) 35(12): 2468–78. doi: 10.1097/HJH.0000000000001474 28708773 · DOI
  112. [114]LaMarca B Wallace K Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol (2011) 11(2): 175–9. doi: 10.1016/j.coph.2011.01.003 PMC3075337 21317038 · DOI
  113. [115]Sahay AS Patil VV Sundrani DP Joshi AA Wagh GN Gupte SA. A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. Hypertens Res (2014) 37(8): 753–8. doi: 10.1038/hr.2014.71 24718301 · DOI
  114. [116]Cunningham MW Jr. Castillo J Ibrahim T Cornelius DC Campbell N Amaral L. AT1-AA (Angiotensin II type 1 receptor agonistic autoantibody) blockade prevents preeclamptic symptoms in placental ischemic rats. Hypertension (2018) 71(5): 886–93. doi: 10.1161/HYPERTENSIONAHA.117.10681 PMC5903585 29555668 · DOI
  115. [117]Menkhorst E Zhou W Santos L Zhang JG St-Pierre Y Young MJ. Galectin-7 dysregulates renin-angiotensin-aldosterone and NADPH oxide synthase pathways in preeclampsia. Pregnancy Hypertens (2022) 30: 130–6. doi: 10.1016/j.preghy.2022.09.008 36183583 · DOI
  116. [118]Bodova KB Biringer K Dokus K Ivankova J Stasko J Danko J. Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia. Dis Markers (2011) 30(4): 191–6. doi: 10.1155/2011/219350 PMC3825071 21694445 · DOI
  117. [119]Zhang Y Liang B Meng F Li H. Effects of nrf-2 expression in trophoblast cells and vascular endothelial cells in preeclampsia. Am J Transl Res (2021) 13(3): 1006–21. PMC8014400 33841636
  118. [120]Parchem JG Kanasaki K Lee SB Kanasaki M Yang JL Xu Y. STOX1 deficiency is associated with renin-mediated gestational hypertension and placental defects. JCI Insight (2021) 6(2): 141588. doi: 10.1172/jci.insight.141588 33301424 PMC7934881 · DOI
  119. [121]van Dijk M Oudejans CB. STOX1: Key player in trophoblast dysfunction underlying early onset preeclampsia with growth retardation. J Pregnancy (2011) 521826(10): 15. doi: 10.1155/2011/521826 PMC3066643 21490791 · DOI
  120. [122]Merrill DC Karoly M Chen K Ferrario CM Brosnihan KB. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine (2002) 18(3): 239–45. doi: 10.1385/ENDO:18:3:239 12450315 · DOI
  121. [123]Wang C Zhou X Liu H Huang S. Three polymorphisms of renin-angiotensin system and preeclampsia risk. J Assist Reprod Genet (2020) 37(12): 3121–42. doi: 10.1007/s10815-020-01971-8 PMC7714824 33230614 · DOI
  122. [124]Yüce M Filiztekin E Özkaya KG. COVID-19 diagnosis -a review of current methods. Biosens Bioelectron (2021) 172: 112752. doi: 10.1016/j.bios.2020.112752 33126180 PMC7584564 · DOI
  123. [125]Chen F Zhu S Dai Z Hao L Luan C Guo Q. Effects of COVID-19 and mRNA vaccines on human fertility. Hum Reprod (2021) 37(1): 5– 13. doi: 10.1093/humrep/deab238 34734259 PMC8689912 · DOI
  124. [126]Jackson CB Farzan M Chen B Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol (2022) 23(1): 3– 20. doi: 10.1038/s41580-021-00418-x 34611326 PMC8491763 · DOI
  125. [127]Madendag IC Madendag Y Ozdemir AT. COVID-19 disease does not cause ovarian injury in women of reproductive age: an observational before-and-after COVID-19 study. Reprod BioMed Online (2022) 45(1): 153–8. doi: 10.1016/j.rbmo.2022.03.002 PMC8897265 35523708 · DOI
  126. [128]Kolanska K Hours A Jonquière L Mathieu d'Argent E Dabi Y Dupont C. Mild COVID-19 infection does not alter the ovarian reserve in women treated with ART. Reprod BioMed Online (2021) 43(6): 1117–21. doi: 10.1016/j.rbmo.2021.09.001 PMC8432972 34711516 · DOI
  127. [129]Bentov Y Beharier O Moav-Zafrir A Kabessa M Godin M Greenfield CS. Ovarian follicular function is not altered by SARS-CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination. Hum Reprod (2021) 36(9): 2506–13. doi: 10.1093/humrep/deab182 PMC8385874 34364311 · DOI
  128. [130]Chadchan SB Popli P Maurya VK Kommagani R. The SARS-CoV-2 receptor, angiotensin-converting enzyme 2, is required for human endometrial stromal cell decidualization†. Biol Reprod (2021) 104(2): 336–43. doi: 10.1093/biolre/ioaa211 PMC7717150 33205194 · DOI
  129. [131]Kala S Dunk C Acosta S Serghides L. Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies. Hum Reprod (2020) 35(8): 1781–96. doi: 10.1093/humrep/deaa151 PMC7398624 32712670 · DOI
  130. [132]Abhari S Kawwass JF. Endometrial susceptibility to SARS CoV-2: explained by gene expression across the menstrual cycle? Fertil Steril (2020) 114(2): 255–6. doi: 10.1016/j.fertnstert.2020.06.046 PMC7324322 32741461 · DOI
  131. [133]Aghaamoo S Ghods K Rahmanian M. Pregnant women with COVID-19: the placental involvement and consequences. J Mol Histol (2021) 52(3): 427–35. doi: 10.1007/s10735-021-09970-4 PMC8053892 33871721 · DOI
  132. [134]Arthurs AL Jankovic-Karasoulos T Roberts CT. COVID-19 in pregnancy: What we know from the first year of the pandemic. Biochim Biophys Acta Mol Basis Dis (2021) 1867(12): 166248. doi: 10.1016/j.bbadis.2021.166248 34461257 PMC8397492 · DOI
  133. [135]Komine-Aizawa S Takada K Hayakawa S. Placental barrier against COVID-19. Placenta (2020) 99: 45–9. doi: 10.1016/j.placenta.2020.07.022 PMC7381919 32755724 · DOI
  134. [136]Geslot A Chanson P Caron P. Covid-19, the thyroid and the pituitary - the real state of play. Ann Endocrinol (Paris) (2022) 83(2): 103–8. doi: 10.1016/j.ando.2021.12.004 PMC8772063 35065920 · DOI
  135. [137]Lisco G De Tullio A Jirillo E Giagulli VA De Pergola G Guastamacchia E. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J Endocrinol Invest (2021) 44(9): 1801–14. doi: 10.1007/s40618-021-01554-z PMC7992516 33765288 · DOI

Cited by

Sorted by citations

Authors
Liu, Y., Hao, H., Lan, T., Jia, R., Cao, M., Zhou, L., Zhao, Z., & Pan, W.
Affiliations
Second Hospital of Hebei Medical University (CN)
Corresponding author
  • Zhao, Zhiming
  • Pan, Wensen
ORCID
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2022-12-23
Volume
13
Pages
1080285-1080285
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2022.1080285
PMC
PMC9817105
OpenAlex
W4312117438
Cited by
20
References
2
Citations by year
2026: 4 · 2025: 5 · 2024: 9 · 2023: 2
FWCI
0.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords
angiotensin II, angiotensin-(1-7), local renin-angiotensin system, female reproductive system, ovary, uterus, placenta, folliculogenesis, uterine physiology, placental physiology, infertility, reproductive disorders, reproductive cancers, angiotensin receptors, therapeutic target
MeSH terms
Angiotensin I, Angiotensin II, Female, Genitalia, Female, Humans, Peptide Fragments, Placenta, Pregnancy, Renin-Angiotensin System

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review